Amantadine in the treatment of Parkinson's disease and other movement disorders.
Rascol O, Fabbri M, Poewe W.
Lancet Neurol. 2021 Dec;20(12):1048-1056. doi: 10.1016/S1474-4422(21)00249-0. Epub 2021 Oct 19.
PMID:34678171
Neuroprotective effects of amantadine for experimental acute carbon monoxide poisoning.
Zengin EN, Kayır S, Doğan G, Zengin M, Akdağlı Ekici A, Yalvaç M, Ayaz E, Özcan O, Karaca O, Yağan Ö, Alagöz A.
Eur Rev Med Pharmacol Sci. 2022 Oct;26(19):6919-6927. doi: 10.26355/eurrev_202210_29872.
PMID:36263571
Amantadine use in the French prospective NS-Park cohort.
Fabbri M, Rousseau V, Corvol JC, Sommet A, Tubach F, De Rycke Y, Bertille N, Selvarasa Y, Carvalho S, Chaigneau V, Brefel-Courbon C, Ory-Magne F, Tessier S, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Schneider V, Moro E, Defebvre L, Houeto JL, Prange S, Eusebio A, Geny C, Frismand S, Damier P, Reuther CG, Castelnovo G, Benatru I, De Maindreville AD, Drapier S, Maltête D, Lagha-Boukbiza O, Rascol O; French N. S.-Park network.